Erschienen in:
29.03.2019 | Focus on
Erenumab: from scientific evidence to clinical practice—the first Italian real-life data
verfasst von:
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi
Erschienen in:
Neurological Sciences
|
Sonderheft 1/2019
Einloggen, um Zugang zu erhalten
Excerpt
Despite the increase in its scientific knowledge and awareness, migraine remains an undertreated illness. Drugs discovered by serendipity still represent the standard of care and are often prematurely discontinued due to side effects, low efficacy, or both. Only two molecules, topiramate and onabotulinum toxin A, have been launched for migraine prevention over the last 28 years. As some efficacious compounds (e.g., methysergide and pizotifen) are no longer available, we must acknowledge that the therapeutic offer for the third most common and second most disabling human disease has been paradoxically declining over time. …